TY - JOUR
T1 - An open multicenter phase II trial of weekly docetaxel for advanced-stage non-small-cell lung cancer in elderly patients with significant comorbidity and/or poor performance status
T2 - The GFPC 02-02b study
AU - LeCaer, Hervé
AU - Barlesi, Fabrice
AU - Robinet, Gilles
AU - Fournel, Pierre
AU - Geriniere, Laurence
AU - Bombaron, Pierre
AU - Falchero, Lionel
AU - Auliac, Jean Baptiste
AU - Crequit, Jacky
AU - Chouaid, Christos
N1 - Funding Information:
This study was supported by Sanofi Aventis Oncology, Jansen Cilag DHRC Assistance Publique Hôpitaux de Marseille.
PY - 2007/7/1
Y1 - 2007/7/1
N2 - Context: The objective of this study was to evaluate the feasibility and activity of weekly docetaxel monotherapy in frail elderly patients with advanced-stage non-small-cell lung cancer, selected on the basis of their precise age, general condition, and number of comorbid disorders (Charlson score). Methods: Analysis of the response rate, toxicity, quality of life, median survival and 1-year survival rates after 1-3 six-week cycles of docetaxel 30 mg/m2 weekly. Results: Fifty patients were enrolled and 42 were assessable. Five patients (10%, [3.7-22.6]) had objective responses, 14 (28%, [16.9-41.6]) had stable disease, and 23 (46%, [32.6-52.8]) progressed. The main grade 3-4 toxicity was fatigue (30%). Quality of life remained stable during treatment. The median survival time was 4.3 months, and the 1-year survival rate was 21.8%. Conclusion: In frail elderly patients selected on the basis of their age, general condition and comorbidity, weekly docetaxel monotherapy has acceptable toxicity and does not negatively affect quality of life. In contrast, it has only moderate activity.
AB - Context: The objective of this study was to evaluate the feasibility and activity of weekly docetaxel monotherapy in frail elderly patients with advanced-stage non-small-cell lung cancer, selected on the basis of their precise age, general condition, and number of comorbid disorders (Charlson score). Methods: Analysis of the response rate, toxicity, quality of life, median survival and 1-year survival rates after 1-3 six-week cycles of docetaxel 30 mg/m2 weekly. Results: Fifty patients were enrolled and 42 were assessable. Five patients (10%, [3.7-22.6]) had objective responses, 14 (28%, [16.9-41.6]) had stable disease, and 23 (46%, [32.6-52.8]) progressed. The main grade 3-4 toxicity was fatigue (30%). Quality of life remained stable during treatment. The median survival time was 4.3 months, and the 1-year survival rate was 21.8%. Conclusion: In frail elderly patients selected on the basis of their age, general condition and comorbidity, weekly docetaxel monotherapy has acceptable toxicity and does not negatively affect quality of life. In contrast, it has only moderate activity.
KW - Chemotherapy
KW - Comorbidity
KW - Elderly
KW - Lung cancer
KW - Phase II trial
UR - http://www.scopus.com/inward/record.url?scp=34249787037&partnerID=8YFLogxK
U2 - 10.1016/j.lungcan.2007.02.012
DO - 10.1016/j.lungcan.2007.02.012
M3 - Article
C2 - 17391803
AN - SCOPUS:34249787037
SN - 0169-5002
VL - 57
SP - 72
EP - 78
JO - Lung Cancer
JF - Lung Cancer
IS - 1
ER -